Navigation Links
Long-term outcomes in patients with advanced coronary artery disease are better than expected
Date:5/15/2013

MINNEAPOLIS (May 15, 2013) Death rates associated with patients with refractory angina, or chronic chest pain, are lower than previously considered; therefore, physicians should focus on relieving the chest pain symptoms and improving the quality of life in these patients according to an article published online this week in the European Heart Journal.

Refractory angina patients endure ongoing chest pain despite optimal medical management and for them, standard revascularization techniques, such as surgery or stenting, is no longer an option. Traditionally, these are the patients with the most advanced coronary artery disease, frequently referred to as "no-option patients."

"Importantly, this study describes the first long-term results from the largest and most contemporary follow-up of patients in a dedicated refractory angina clinic," says the study's first author Timothy D. Henry, MD, director of research at the Minneapolis Heart Institute Foundation. "Our results demonstrate that long-term mortality in patients with refractory angina is surprisingly low, below 4 percent per year."

The OPtions In Myocardial Ischemic Syndrome Therapy (OPTIMIST) program at the Minneapolis Heart Institute at Abbott Northwestern Hospital in Minneapolis was created for refractory angina patients in 1996 to develop new treatment options for this challenging patient population. This study reflects the long-term survival and predictors of mortality.

The study population consisted of 1,200 consecutive patients with either refractory myocardial ischemia and/or refractory angina, who were not candidates for traditional revascularization and referred for alternative treatment strategies from 1996 to present.

Overall, 241 patients of the 1,200 died during a median follow-up of 5.1 years. After an analysis, the researchers determined mortality was 3.9 percent at one year and 28.4 percent at nine years.

"Currently, data on the incidence and prevalence of refractory angina are scarce and mainly derived from registries," explains Henry.

In addition to the low overall mortality, the results indicated non-cardiac death in nearly 30 percent of patients and a low incidence of sudden cardiac death.

Improved secondary prevention strategies, evidence-based medical therapy and more advanced revascularization techniques all likely contributed to lower mortality, concluded Henry and his colleagues in the paper.

"Widespread and improved adherence to medical medications combined with aggressive lifestyle changes, such as diet, exercise and smoking cessation, has contributed to lower overall mortality in patients with coronary artery disease, and this includes the highest-risk patients with refractory angina," Henry notes.

Based on the findings, more than 70 percent of patients with refractory angina can expect to survive nine years from the time of diagnosis. Given these results, the researchers emphasized that therapeutic options for this growing population should therefore focus on chest pain relief and improved quality of life.


'/>"/>

Contact: Steve Goodyear
sgoodyear@mhif.org
612-863-1658
Minneapolis Heart Institute Foundation
Source:Eurekalert

Related medicine news :

1. Erectile Dysfunction Tied to Long-Term Narcotic Use in Men
2. Long-term use of prescription painkillers for back pain linked to erectile dysfunction in men
3. BMA Affordable Assisted Living Community to Host Informational Program on Long-Term Care Insurance
4. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers New Unlimited Support To Dieters, Making the Transfer to Long-term Improved Health Easier
5. A "FAST" Response to Stroke Can Reduce Long-Term Damage
6. Chickenpox Shot Provides Long-Term Protection, Study Finds
7. Varicella vaccine has long-term effectiveness against chicken pox
8. New mechanism for long-term memory formation discovered
9. False-Positive Mammograms Can Trigger Long-Term Distress
10. Breast Cancer Radiation Has Long-Term Heart Effects: Study
11. Can hormone help treat multiple sclerosis long-term?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/24/2017)... ... August 24, 2017 , ... ... coding, billing and compliance. In the coming months, AudioEducator has lined up several ... all specialties. Delivered by nationally recognized experts, these healthcare training conferences are designed ...
(Date:8/23/2017)... ... August 23, 2017 , ... Loyale Healthcare today ... Mr. Smith joins other recent high-profile hires including Frank Massi, Chief Revenue Officer ... in 1993, helping physician practices and hospitals automate their clinical and financial processes ...
(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... The Stevie® Awards have announced the winners ... Awards , the world’s premier business awards competition. , Nominees in the 2017 IBAs were ... by a points system based on the total number of awards won in the IBAs ...
(Date:8/23/2017)... Indiana (PRWEB) , ... August 23, 2017 , ... ... Whitney Boling, MD , has returned home to Indiana, and is now seeing ... is a board-eligible ophthalmologist that specializes in the diagnosis and treatment of eye ...
(Date:8/23/2017)... Rosa, CA (PRWEB) , ... August 23, 2017 ... ... the Journal of the American Academy of Orthopaedic Surgeons , points out ... for patients suffering from pain or injury. According to the report, a wider ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... , Aug. 7, 2017 Insightin ... member acquisition, retention, and engagement, announced the selection ... Strategy and Product Development, effective as of February 2017. ... and technology implementation strategy for our clients. Wood ... experience in consulting and business analytics within the ...
(Date:8/7/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent specialty ... 2017.  All comparisons, unless otherwise noted, are to the quarter ... Second Quarter 2017 Highlights include: ... of 3.5% Total prescriptions dispensed of 220,000, ... versus 7.6% Gross profit per prescription ...
(Date:8/4/2017)...  Agragen, LLC, a Cincinnati ... nutraceutical, and aquacultural feed sectors, announces a significant ... candidates, AGR131.  This drug is designed to trap ... of patients suffering from inflammatory conditions such as ... Biological pharmaceuticals currently ...
Breaking Medicine Technology: